MedTrace Logo

Clinical Study on ShouTai Pills for Improving Reduced Ovarian Reserve

NCT07737847 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-07-30

No results posted yet for this study

Summary

Grounded in the 'disease-syndrome combination' paradigm, this study endeavors to address the pivotal scientific issues pertaining to the clinical precision of Traditional Chinese Medicine (TCM) in managing Diminished Ovarian Reserve (DOR) classified as the Kidney Essence Deficiency type, through the application of systems biology technologies, including metabolomics.

Conditions

  • Diminished Ovarian Reserve (DOR)

Interventions

DRUG

Placebo

The experimental group took placebo Pills, 20 pills each time, twice daily, taken with water, continuously for 3 months

DRUG

Shoutai Pill

The experimental group took Shoutai Pills, 20 pills each time, twice daily, taken with water, continuously for 3 months

Sponsors & Collaborators

  • Beijing Municipal Health Commission

    collaborator OTHER_GOV

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07737847 on ClinicalTrials.gov